Treating in the dark: Unanswered questions on costs and benefits of late line therapy for metastatic breast cancer

Cancer Investigation

Volumn 27, Issue 1, 2009, Pages 13-16

  Anders, Carey K ^a   Peppercorn, Jeffrey ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Late line treatment; Metastatic breast cancer

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB;

BREAST CANCER; BREAST METASTASIS; BUDGET; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG TOLERABILITY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; NOTE; OVERALL SURVIVAL; PATIENT DECISION MAKING; PRIORITY JOURNAL; QUALITY OF LIFE; RETROSPECTIVE STUDY; SURVIVAL TIME; TERMINAL CARE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MODELS, ECONOMIC; TIME FACTORS;

EID: 60549087183     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802484944     Document Type: Note

References (14)

1. Ries, L.A.G.; Melbert, D.; Krapcho, M.; Stinchcomb, D.G.; Howlader, N.; Horner, M.J.; et al. (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2005, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
2. Dawood, S.; Broglio. K.; Hortobagyi, G.; Giordano, S. Trends in survival of stage iv breast cancer (bc) among Caucasian and African American (AA) bc patients (pts). J Clin Oncol 2007. ASCO Annual Meeting Proceedings, 25 (Abstract 1000).
3. American Cancer Society. Breast Cancer Facts & Figures 2007-2008. Atlanta, GA: American Cancer Society, Inc; 2007-2008.
4. Lu, C.; Lin, Y.; Chang, H. Weekly paclitaxel in women with heavily pretreated metastatic breast cancer: a retrospective analysis of cases treated at the Chang Gung Memorial Hospital. Chang Gung Med J 2007, 30, 33-40.
5. Grothey, A.; Sugrue, M.; Hedrick, E.; Purdie, D.; Yi, J.D.; Kozloff, M. Investigators tBS: association between exposure to bevacizumab (bv) beyond first progression (bbp) and overall surivival (os) in patients with metastatic colorectal cancer (mcrc): results from a large observational study (BRITE). J Clin Oncol 2007. ASCO Annual Meeting Proceedings Part 1 (June 20, Supplement) 25, Abstract 4036.
6. Tripathy, D.S.; Slamon, D.J.; Cobleigh, M.; Arnold, A.; Salah, M.; Mortimer, J.E.; et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004, 22, 1063-1070.
7. Goetz, M.; Knox, S.; Suman, V.; Rae, J.; Safgren, S.; Ames, M.; et al. The impact of cytochrome p450 2d6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007, 101, 113-121.
8. Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351, 2817-2826.
9. Del Bianco, S.; Rondinelli, R. Trastuzumab-containing therapies: activity beyond disease progression in MBC - a pivotal experience. J Clin Oncol 2006. ASCO Annual Meeting Proceedings Part I 24(18S) (June 20 Supplement) 10788.
10. Garcia-Saenz, J.; Martin, M.; Bueno, C.; Sampedro, T.; Lopez-Tarruella, S.; et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. J Clin Oncol 2006. ASCO Annual Meeting Proceedings Part I 24(18S) (June 20 Supplement), Abstract 10617.
11. Sorlie, T.; Perou, C.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H. et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 2001, 98, 10869-10874.
12. Carey, L.A.; Rugo, H.S.; Marcom, P.K.; Irvin, W.; Ferraro, M.; Burrows, E.; et al. Tbcrc 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J. Clin. Oncol. ASCO Annual Meeting Proceedings 2008, 26, Abstract 1009.
13. Zhang, B.; Wright, A.A.; Nilsson, M.E.; Huskamp, H.A.; Maciejewski, M.L.; Earle, C.C.; et al. Associations between advanced cancer patients' end-of-life conversations and cost experiences in the final week of life. J Clin Oncol 2008. ASCO Annual Meeting Proceedings 26, 9530.
14. Peppercorn, J.; Blood, E.; Winer, E.; Partridge, A. Association between pharmaceutical involvement and outcomes in breast cancer clinical trials. Cancer 2007, 109, 1239-1246.